Patents Examined by Bruce R. Campell
  • Patent number: 7645456
    Abstract: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: January 12, 2010
    Assignee: Sanofi Pasteur Biologics Co.
    Inventors: Richard A. Weltzin, Thomas P. Monath
  • Patent number: 7534435
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: May 19, 2009
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Patent number: 7510868
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: March 31, 2009
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Patent number: 7442550
    Abstract: A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: October 28, 2008
    Assignees: Biomerieux, Institut National de la Sante et de la Recherche Medicale
    Inventors: Francois Mallet, Francois-Loic Cosset, Jean-Luc Blond, Dimitri Lavillette, Olivier Bouton, Alessia Ruggieri
  • Patent number: 7439041
    Abstract: Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described. Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for prions and prion-associated diseases are also described.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: October 21, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Melissa D. Michelitsch, Celine Y-H. Hu
  • Patent number: 7425618
    Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: September 16, 2008
    Assignee: Medimmune, Inc.
    Inventors: Cynthia N. Oliver, Christian B. Allan, Stephen T. Chang
  • Patent number: 7417122
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 26, 2008
    Assignee: Schering Corporation
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 7404956
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: July 29, 2008
    Assignee: Syntonix Pharmaceuticals, Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Patent number: 7402396
    Abstract: Described are the crystal structure of the ?-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: July 22, 2008
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David C. Chan, Deborah Fass, Min Lu, James M. Berger, Peter S. Kim
  • Patent number: 7399468
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: July 15, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Martin Mueller, Sybille Albrecht, Viktor Magdolen, Olaf Wilhelm, Manfred Schmitt, Nadja Harbeck
  • Patent number: 7399825
    Abstract: The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which contains the active domain and which we have named Herp. Herp mimics the activity of Herpoxin in inhibiting the replication of DNA viruses. A synthetic version of the active fragment was produced having the amino acid sequence Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln. The synthetic version of Herp consisting of ten amino acids inhibits the replication of DNA viruses such as herpes viruses types 1 and 2, cytomegalovirus and varicella zoster virus as well as Tubercle bacilli.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: July 15, 2008
    Inventors: Binie V. Lipps, Frederick W. Lipps
  • Patent number: 7393658
    Abstract: Prion protein binding materials and methods for using the binding materials to detect or remove a prion protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), recombinant prion protein (PrPr), and proteinase resistant prion protein (PrPres). Prions from various species, including humans and hamsters, are bound by the binding materials.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: July 1, 2008
    Assignees: Pathogen Removal and Diagnostic Technologies, Inc., North Carolina State University
    Inventors: Ruben G. Carbonell, Honglue Shen, Patrick V. Gurgel, Viteros Wiltshire-Lyerly, David J. Hammond, Steven J. Burton
  • Patent number: 7393933
    Abstract: A monoclonal antibody that is capable of binding specifically to wild type HBsAg and to at least two mutant forms of HBsAg may be used in an improved immunoassay for the detection of both escape mutants and wild type HBsAg and may be used for passive immunisation against HBV.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: July 1, 2008
    Inventors: Richard Seton Tedder, Samreen Ijaz, Ruth Bridget Ferns
  • Patent number: 7387886
    Abstract: Described is a prion protein, wherein said prion protein is a homodimer or heterodimer. The prion protein dimers are highly immunogenic capable of inducing an immune response in a mammal, thus useful for prophylactic or therapeutic vaccination against diseases associated with the infectious forms of prion proteins, PrPSc, i.e. transmissible spongiform encephalopathies. Moreover, antibodies generated by using the prion protein diners as an antigen, pharmaceutical composition containing the prion protein dimers or antibodies directed against said diners as well as DNA sequences encoding the prion protein diners are described.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: June 17, 2008
    Inventor: Hermann Schaetzl
  • Patent number: 7385049
    Abstract: The invention provides methods of detecting West Nile virus and oligonucleotide reagents derived from a West Nile virus consensus sequence that are useful in the methods of the invention.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: June 10, 2008
    Assignee: Bayer HealthCare LLC
    Inventors: Stefan H. M. Burde, Todd M. Gierman, Christopher C. Glenn
  • Patent number: 7384785
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: June 10, 2008
    Assignee: Health Research, Inc.
    Inventors: Susan J. Wong, Pei-Yong Shi
  • Patent number: PP21118
    Abstract: A new and distinct cultivar of Petunia plant named ‘MP3’, characterized by its compact and outwardly spreading plant habit; freely and continuous branching habit; small leaf size; numerous small dark violet-colored flowers; and resistance to Botrytis and Powdery Mildew.
    Type: Grant
    Filed: September 29, 2002
    Date of Patent: June 29, 2010
    Assignee: NuFlora International Pty. Ltd.
    Inventor: Graham Noel Brown
  • Patent number: PP21862
    Abstract: A new and distinct Miniature Rose plant having attractive Red flowers.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: April 12, 2011
    Assignee: Nor'East Miniature Roses, Inc.
    Inventor: John M. Saville
  • Patent number: RE47177
    Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties include increased resistance to photodamage, and can also include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: December 25, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Arek Bibillo, Keith Bjornson, Fred Christians, Colleen Cutcliffe, Jeremiah Hanes, Lei Jia, Walter Lee, Erik Miller, Pranav Patel
  • Patent number: RE47222
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Pep Tcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley